• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Final Participating Company Line-Up Announced for the Virtual Investor Pitch Conference Hosted by JTC Team Being Held June 17 - 18, 2024

    6/17/24 8:00:00 AM ET
    $AIM
    $ANVS
    $AREC
    $GRI
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $AIM alert in real time by email

    - Two-day conference with live video webcast presentations and Q&A beginning today, June 17th at 9:00 AM ET

    - Full schedule of participating companies now available at www.virtualinvestorco.com

    FRENCHTOWN, NJ / ACCESSWIRE / June 17, 2024 / JTC Team ("JTC"), a fully integrated corporate communications and investor relations firm, today announced the final participating company line-up for the two-day Virtual Investor Pitch Conference beginning today, Monday, June 17, 2024.

    For the event, participating companies will provide their "elevator pitch" and outline upcoming milestones. Additionally, investors and interested parties will have the opportunity to submit questions live during the event. Participating companies will answer as many questions as possible in the time allowed.

    The final schedule of participating companies is as follows:

    Monday, June 17

    • 9:00 AM ET: Kaida BioPharma, Inc. (Private) - Webcast
    • 10:00 AM ET: Adolore BioTherapeutics, Inc. (Private) - Webcast
    • 12:00 PM ET: Palisade Bio, Inc. (NASDAQ:PALI) - Webcast
    • 1:00 PM ET: AIM ImmunoTech Inc. (NYSE:AIM) - Webcast
    • 4:00 PM ET: enVVeno Medical Corporation (NASDAQ:NVNO) - Webcast

    Tuesday, June 18

    • 10:00 AM ET: Royalty Management Holding Corporation (NASDAQ:RMCO) - Webcast
    • 11:00 AM ET: GRI Bio, Inc. (NASDAQ:GRI) - Webcast
    • 12:00 PM ET: Outlook Therapeutics, Inc. (NASDAQ:OTLK) - Webcast
    • 1:00 PM ET: American Resources Corporation (NASDAQ:AREC) - Webcast
    • 2:00 PM ET: Annovis Bio Inc. (NYSE:ANVS) - Webcast
    • 3:00 PM ET: Moleculin Biotech, Inc. (NASDAQ:MBRX) - Webcast

    All investors and interested parties can access the event schedule and individual company webcast details at www.virtualinvestorco.com. Webcast replays will be made available shortly after the conclusion of the live event and will be accessible for 90 days.

    To access all Virtual Investor events, visit www.virtualinvestorco.com.

    About JTC Team

    JTC is a fully integrated investor relations firm that is dedicated to helping you tell your story to the right audiences in order to build awareness. JTC has developed a reputation of excellence for executing on robust communication strategies that deliver results. The Company partners with both public and private companies across the Life Sciences and Technology industries to help raise awareness and build stakeholder value. For more information, please visit www.jtcir.com or connect with the company on X and LinkedIn.

    Contact:

    Jenene Thomas
    JTC Team, LLC
    T: +1 (833) 475-8247
    jtc@jtcir.com

    SOURCE: JTC Team, LLC



    View the original press release on accesswire.com

    Get the next $AIM alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $AIM
    $ANVS
    $AREC
    $GRI

    CompanyDatePrice TargetRatingAnalyst
    Annovis Bio Inc.
    $ANVS
    7/8/2026$8.00Buy
    Roth Capital
    Outlook Therapeutics Inc.
    $OTLK
    5/18/2026Buy → Neutral
    BTIG Research
    Palisade Bio Inc.
    $PALI
    4/9/2026$7.00Outperform
    Wolfe Research
    Palisade Bio Inc.
    $PALI
    3/26/2026$7.00Buy
    H.C. Wainwright
    Palisade Bio Inc.
    $PALI
    2/25/2026$5.00Buy
    Stifel
    Palisade Bio Inc.
    $PALI
    1/9/2026$7.00Buy
    B. Riley Securities
    Palisade Bio Inc.
    $PALI
    12/29/2025$25.00Overweight
    Piper Sandler
    American Resources Corporation
    $AREC
    11/26/2025$7.00Buy
    Maxim Group
    More analyst ratings

    $AIM
    $ANVS
    $AREC
    $GRI
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Roth Capital initiated coverage on Annovis Bio with a new price target

    Roth Capital initiated coverage of Annovis Bio with a rating of Buy and set a new price target of $8.00

    7/8/26 9:18:09 AM ET
    $ANVS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Outlook Therapeutics downgraded by BTIG Research

    BTIG Research downgraded Outlook Therapeutics from Buy to Neutral

    5/18/26 8:32:11 AM ET
    $OTLK
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Wolfe Research initiated coverage on Palisade Bio with a new price target

    Wolfe Research initiated coverage of Palisade Bio with a rating of Outperform and set a new price target of $7.00

    4/9/26 8:43:44 AM ET
    $PALI
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $AIM
    $ANVS
    $AREC
    $GRI
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Baltera Robert Jr. bought $88,698 worth of shares (45,000 units at $1.97), increasing direct ownership by 11% to 461,904 units (SEC Form 4)

    4 - PALISADE BIO, INC. (0001357459) (Issuer)

    7/10/26 6:14:21 PM ET
    $PALI
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Director Baltera Robert Jr. bought $102,084 worth of shares (50,000 units at $2.04), increasing direct ownership by 14% to 416,904 units (SEC Form 4)

    4 - PALISADE BIO, INC. (0001357459) (Issuer)

    7/8/26 6:56:16 PM ET
    $PALI
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Chief Medical Officer Jones Mitchell Lawrence converted options into 131,167 shares and sold $106,536 worth of shares (51,880 units at $2.05), increasing direct ownership by 539% to 94,009 units (SEC Form 4) to satisfy tax liability

    4 - PALISADE BIO, INC. (0001357459) (Issuer)

    7/8/26 6:52:59 PM ET
    $PALI
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $AIM
    $ANVS
    $AREC
    $GRI
    SEC Filings

    View All

    SEC Form EFFECT filed by Outlook Therapeutics Inc.

    EFFECT - Outlook Therapeutics, Inc. (0001649989) (Filer)

    7/22/26 12:15:12 AM ET
    $OTLK
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form 424B3 filed by Outlook Therapeutics Inc.

    424B3 - Outlook Therapeutics, Inc. (0001649989) (Filer)

    7/21/26 4:37:38 PM ET
    $OTLK
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    American Resources Corporation filed SEC Form 8-K: Other Events

    8-K - American Resources Corp (0001590715) (Filer)

    7/21/26 9:15:44 AM ET
    $AREC
    Coal Mining
    Energy

    $AIM
    $ANVS
    $AREC
    $GRI
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Palisade Bio to Participate in the Leerink Partners Therapeutics Forum

    Management to participate in investor meetings on July 14-15 in Boston Denver, CO, July 10, 2026 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (NASDAQ:PALI) ("Palisade" or the "Company"), a clinical-stage biopharmaceutical company developing next-generation oral PDE4 inhibitor prodrugs for inflammatory bowel disease, today announced that JD Finley, Chief Executive Officer, and Dr. Mitchell Jones, President & Chief Medical Officer, will participate in the Leerink Partners Therapeutics Forum, taking place July 14-15, 2026, in Boston, Massachusetts. Management will participate in one-on-one meetings with institutional investors throughout the conference to discuss the Company's clinical developmen

    7/10/26 9:00:00 AM ET
    $PALI
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    AIM ImmunoTech Announces Release of New CEO Corner Segment Highlighting Growing Momentum Across Pancreatic Cancer Program

    Access it here OCALA, Fla., July 07, 2026 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE:AIM) ("AIM" or the "Company") today announced the release of its latest CEO Corner segment, featuring Chief Executive Officer Thomas Equels discussing the Company's continued momentum in pancreatic cancer and the significant clinical, strategic and operational milestones positioning Ampligen® for its next stage of development. In the segment, Mr. Equels highlights the urgent unmet need facing patients with pancreatic cancer, reviews recent progress across the Company's DURIPANC Phase 2 clinical program evaluating Ampligen® (rintatolimod) in combination with AstraZeneca's Imfinzi® (durvalumab), and dis

    7/7/26 9:03:00 AM ET
    $AIM
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Annovis Reaches Full Enrollment in Pivotal Phase 3 Trial of Buntanetap for Early Alzheimer’s Disease

    Pivotal Phase 3 trial enrolls 850 patients, exceeding original projections Study completion on track: symptomatic data readout - Q1 2027, disease-modifying data readout - Q1 2028 Company positions for two NDA submissions following each readout MALVERN, Pa., July 07, 2026 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE:ANVS) ("Annovis" or the "Company"), a Phase 3 clinical-stage biotechnology company developing the investigational oral therapy, buntanetap, for neurodegenerative diseases such as Alzheimer’s disease (AD) and Parkinson’s disease (PD), today announced full enrollment of its pivotal Phase 3 trial (NCT06709014) evaluating buntanetap in patients with early AD. The trial enrolled 85

    7/7/26 7:00:00 AM ET
    $ANVS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AIM
    $ANVS
    $AREC
    $GRI
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Baltera Robert Jr. bought $88,698 worth of shares (45,000 units at $1.97), increasing direct ownership by 11% to 461,904 units (SEC Form 4)

    4 - PALISADE BIO, INC. (0001357459) (Issuer)

    7/10/26 6:14:21 PM ET
    $PALI
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Director Baltera Robert Jr. bought $102,084 worth of shares (50,000 units at $2.04), increasing direct ownership by 14% to 416,904 units (SEC Form 4)

    4 - PALISADE BIO, INC. (0001357459) (Issuer)

    7/8/26 6:56:16 PM ET
    $PALI
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Director Baltera Robert Jr. bought $59,400 worth of shares (30,000 units at $1.98), increasing direct ownership by 9% to 366,904 units (SEC Form 4)

    4 - PALISADE BIO, INC. (0001357459) (Issuer)

    7/6/26 7:48:29 PM ET
    $PALI
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $AIM
    $ANVS
    $AREC
    $GRI
    Financials

    Live finance-specific insights

    View All

    Moleculin Reports First Quarter 2026 Financial Results and Provides Clinical Update on Pivotal MIRACLE Trial

    Early blinded results show 40% composite complete remission rate across difficult-to-treat AML patient population in MIRACLE Trial First interim unblinding expected in June 2026 following 45 subject enrollment milestone achieved in MIRACLE trial Enrollment in MIRACLE trial continues to advance on pace with 90th subject expected in Q3 2026 HOUSTON, May 15, 2026 (GLOBE NEWSWIRE) -- Moleculin Biotech, Inc., (NASDAQ:MBRX) ("Moleculin" or the "Company"), today reported financial results for the first quarter ended March 31, 2026 and provided a corporate update. "With enrollment now surpassing the first interim analysis threshold in the MIRACLE trial, we are just weeks away from beginning wh

    5/15/26 8:30:00 AM ET
    $MBRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Palisade Bio Reports Positive Topline Data from Phase 1b Clinical Study of PALI-2108 in Fibrostenotic Crohn's Disease

    PALI-2108 demonstrated favorable safety and tolerability with no serious adverse events after two weeks of treatment in a difficult-to-treat populationPhase 1b data demonstrate endoscopic improvement, with a 47.5% reduction in SES-CD score and 40% of patients achieving endoscopic response and 40% of patients achieving endoscopic remissionPharmacokinetic and pharmacodynamic data from ileal tissue and plasma support once-daily oral dosing for Crohn's disease showing IC90 coverage, with correlation to accepted inflammatory biomarkers Data support expansion into broader luminal CD, an indication that has regulatory clarity, more than doubles the total addressable patient population, and has no a

    3/30/26 4:01:00 PM ET
    $PALI
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Moleculin Reports Full Year 2025 Financial Results and Confirms Highly Anticipated 45-Patient Interim Data Unblinding in Pivotal MIRACLE Trial On Track for Mid-2026

    Miracle Trial Preliminary Blinded CRc Rate of 40% in First 30 Patients Suggests Encouraging Early Results in Relapsed/Refractory AML HOUSTON, March 19, 2026 (GLOBE NEWSWIRE) -- Moleculin Biotech, Inc., (NASDAQ:MBRX) ("Moleculin" or the "Company"), today reported financial results for the year ended December 31, 2025 and provided a clinical update highlighting rapid progress toward a major upcoming milestone in its pivotal MIRACLE trial of Annamycin in combination with cytarabine for the treatment of adult patients with acute myeloid leukemia (AML) who are refractory to or relapsed (R/R) after induction therapy (R/R AML). "With the MIRACLE trial rapidly progressing and the first MIRACLE i

    3/19/26 8:36:00 AM ET
    $MBRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AIM
    $ANVS
    $AREC
    $GRI
    Leadership Updates

    Live Leadership Updates

    View All

    Annovis Appoints Cheng Fang, Ph.D., as Chief Scientific Officer

    MALVERN, Pa., July 01, 2026 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE:ANVS) ("Annovis" or the "Company"), a Phase 3 clinical-stage biotechnology company developing the investigational oral therapy, buntanetap, for neurodegenerative diseases such as Alzheimer’s disease (AD) and Parkinson’s disease (PD), today announced the promotion of Cheng Fang, Ph.D., to Chief Scientific Officer. Dr. Fang, who joined Annovis in 2021 and most recently served as Senior Vice President, Research and Development, will lead scientific strategy and research operations across the Company's AD and PD programs, including translational science, clinical development, biomarker strategy, and regulatory interaction

    7/1/26 8:00:00 AM ET
    $ANVS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Palisade Bio Welcomes Biopharmaceutical Industry Veterans Robert Baltera and Jordan Zwick to its Board of Directors

    Board strengthened with extensive biotechnology leadership, strategic transactions and capital markets expertise Company continues to build on PALI-2108 clinical progress as it advances toward Phase 2 development and additional key milestones Denver, CO, June 11, 2026 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (NASDAQ:PALI) ("Palisade" or the "Company"), a clinical-stage biopharmaceutical company developing next-generation, once-daily, oral PDE4 inhibitor prodrugs designed for targeted delivery to the terminal ileum and colon, today announced the addition of Robert Baltera and Jordan Zwick to its Board of Directors. "We are pleased to welcome both Robert and Jordan to the Palisade Bio Board

    6/11/26 8:45:00 AM ET
    $PALI
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Palisade Bio Appoints Global IBD Precision Medicine Leader Bram Verstockt, MD, PhD to Clinical Advisory Board

    Appointment strengthens Phase 2 development strategy for PALI-2108 in ulcerative colitis and fibrostenotic Crohn's disease; Phase 2 ulcerative colitis IND submission planned for first half of 2026 Carlsbad, CA, Feb. 17, 2026 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (NASDAQ:PALI) ("Palisade" or the "Company"), a clinical-stage biopharmaceutical company advancing next-generation, once-daily oral PDE4 inhibitor prodrugs engineered for targeted delivery to the terminal ileum and colon, today announced the appointment of Bram Verstockt, MD, PhD, to its Clinical Advisory Board (CAB). Dr. Verstockt is an internationally recognized expert in inflammatory bowel disease (IBD) and a leader in precisi

    2/17/26 8:45:00 AM ET
    $PALI
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $AIM
    $ANVS
    $AREC
    $GRI
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13D/A filed by AIM ImmunoTech Inc.

    SC 13D/A - AIM ImmunoTech Inc. (0000946644) (Subject)

    12/17/24 4:11:23 PM ET
    $AIM
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Amendment: SEC Form SC 13G/A filed by Moleculin Biotech Inc.

    SC 13G/A - Moleculin Biotech, Inc. (0001659617) (Subject)

    11/14/24 5:12:06 PM ET
    $MBRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Outlook Therapeutics Inc.

    SC 13G/A - Outlook Therapeutics, Inc. (0001649989) (Subject)

    11/14/24 4:55:26 PM ET
    $OTLK
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care